The causal relationship between systemic lupus erythematosus and juvenile myoclonic epilepsy: A Mendelian randomization study and mediation analysis

Abstract

This study aimed to investigate the causal relationship between systemic lupus erythematosus (SLE) and juvenile myoclonic epilepsy (JME). Univariable and reverse Mendelian randomization (MR) analyses were performed to investigate the potential causal associations between SLE, systemic autoimmune disorders (SADs), and JME. Two-step mediation MR analysis was further performed to explore indirect factors that may influence the relationship between SLE and JME. Summary data on SADs were extracted from the Integrative Epidemiology Unit Open genome-wide association study database, and summary statistics for JME were acquired from the International League Against Epilepsy Consortium. The inverse-variance weighted (IVW) method was used for primary analysis, supplemented by MR-Egger and weighted median. In the univariable MR analysis, IVW results indicated a causal relationship between SLE and an increased risk of JME (odds ratio = 1.0030, 95% confidence interval, 1.0004–1.0057; p = 0.023). The subsequent mediation MR analysis showed that inflammatory cytokines may not be the mediating factors between SLE and JME, while the inverse MR analysis found no significant relationship. Our study indicated that genetic susceptibility to SLE was causally linked to JME. However, subsequent mediation analysis failed to identify the potential mediators that could influence this relationship. Moreover, evidence suggested that other SADs were not causally associated with JME. This study may provide guidance for screening risk factors for seizures and exploring potential treatments in SLE and JME, and even all SADs and JME.

Keywords

causality / inflammatory cytokines / juvenile myoclonic epilepsy / Mendelian randomization / systemic lupus erythematosus

References

[1] Lin Z, Si Q, Xiaoyi Z. Association between epilepsy and systemic autoimmune diseases: a meta-analysis. Seizure. 2016; 41: 160-166.

[2] Steriade C, Titulaer MJ, Vezzani A, Sander JW, Thijs RD. The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain. 2021; 144(2): 372-390.

[3] Amanat M, Thijs RD, Salehi M, Sander JW. Seizures as a clinical manifestation in somatic autoimmune disorders. Seizure. 2019; 64: 59-64.

[4] Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014; 71(5): 569-574.

[5] Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020; 172(11): ITC81-ITC96.

[6] Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021; 11(7):928.

[7] Grasso EA, Cacciatore M, Gentile C, Breda L, Giacomelli R, Verrotti A. Epilepsy in systemic lupus erythematosus. Clin Exp Rheumatol. 2021; 39(3): 651-659.

[8] Hopia L, Andersson M, Svenungsson E, Khademi M, Piehl F, Tomson T. Epilepsy in systemic lupus erythematosus: prevalence and risk factors. Eur J Neurol. 2020; 27(2): 297-307.

[9] Rodriguez-Hernandez A, Ortiz-Orendain J, Alvarez-Palazuelos LE, Gonzalez-Lopez L, Gamez-Nava JI, Zavala-Cerna MG. Seizures in systemic lupus erythematosus: a scoping review. Seizure. 2021; 86: 161-167.

[10] Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus - a retrospective cohort study. Neuropsychiatr Dis Treat. 2014; 10: 1635-1643.

[11] Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia. 1994; 35(suppl 2): 1-6.

[12] Serafini A, Gerard E, Genton P, Crespel A, Gelisse P. Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential. CNS Drugs. 2019; 33(3): 195-208.

[13] Bowden J, Holmes MV. Meta-analysis and mendelian randomization: a review. Res Synth Methods. 2019; 10(4): 486-496.

[14] Richmond RC, Davey Smith G. Mendelian randomization: concepts and scope. Cold Spring Harb Perspect Med. 2022; 12(1):a040501.

[15] Bentham J, Morris DL, Cunninghame Graham DS, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015; 47(12): 1457-1464.

[16] Forgetta V, Manousaki D, Istomine R, et al. Rare genetic variants of large effect influence risk of type 1 diabetes. Diabetes. 2020; 69(4): 784-795.

[17] Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9): 979-986.

[18] Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet. 2011; 43(12): 1193-1201.

[19] Suhre K, Arnold M, Bhagwat AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017; 8:14357.

[20] Abou-Khalil B, Auce P, Avbersek A, et al. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun. 2018; 9(1): 5269.

[21] Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023; 82(8): 999-1014.

[22] Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023; 19(8): 509-524.

[23] Karaaslan Z, Ekizoğlu E, Tektürk P, et al. Investigation of neuronal auto-antibodies in systemic lupus erythematosus patients with epilepsy. Epilepsy Res. 2017; 129: 132-137.

[24] Ganor Y, Goldberg-Stern H, Amrom D, et al. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy. Clin Dev Immunol. 2004; 11(3-4): 241-252.

[25] Orme ME, Voreck A, Aksouh R, Ramsey-Goldman R, Schreurs MWJ. Systematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay. Autoimmun Rev. 2021; 20(11):102943.

[26] Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res. 2005; 65(1-2): 11-22.

[27] Fleetwood T, Cantello R, Comi C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol. 2018; 9:1001.

[28] Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006; 15(4): 191-197.

[29] Liou HH, Wang CR, Chou HC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994; 54(15): 1119-1125.

[30] Shaban A, Leira EC. Neurological complications in patients with systemic lupus erythematosus. Curr Neurol Neurosci Rep. 2019; 19(12): 97.

[31] Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun. 2020; 110:102374.

[32] Soltani Khaboushan A, Yazdanpanah N, Rezaei N. Neuroinflammation and proinflammatory cytokines in epileptogenesis. Mol Neurobiol. 2022; 59(3): 1724-1743.

[33] Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med. 2023; 74: 339-352.

[34] Andersson U, Rauvala H. Introduction: HMGB1 in inflammation and innate immunity. J Intern Med. 2011; 270(4): 296-300.

[35] Liu T, Son M, Diamond B. HMGB1 in systemic lupus erythematosus. Front Immunol. 2020; 11:1057.

[36] Yao M, Zhang C, Gao C, et al. Exploration of the shared gene signatures and molecular mechanisms between systemic lupus erythematosus and pulmonary arterial hypertension: evidence from transcriptome data. Front Immunol. 2021; 12:658341.

[37] Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy. 2020; 16(1): 3-17.

[38] Zhang S, Chen F, Zhai F, Liang S. Role of HMGB1/TLR4 and IL-1β/IL-1R1 signaling pathways in epilepsy. Front Neurol. 2022; 13:904225.

[39] Hreggvidsdottir HS, Östberg T, Wähämaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009; 86(3): 655-662.

[40] Biswas S, Bieber K, Manz RA. IL-10 revisited in systemic lupus erythematosus. Front Immunol. 2022; 13:970906.

[41] Lim SH, Park E, You B, et al. Neuronal synapse formation induced by microglia and interleukin 10. PLoS One. 2013; 8(11):e81218.

[42] Dar SA, Janahi EMA, Haque S, et al. Superantigen influence in conjunction with cytokine polymorphism potentiates autoimmunity in systemic lupus erythematosus patients. Immunol Res. 2016; 64(4): 1001-1012.

[43] Wang JB, Li H, Wang LL, Liang HD, Zhao L, Dong J. Role of IL-1β, IL-6, IL-8 and IFN-γ in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematous. Int J Clin Exp Med. 2015; 8(9): 16658-16663.

[44] Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016; 15(2): 124-138.

[45] Mukhtar I. Inflammatory and immune mechanisms underlying epileptogenesis and epilepsy: from pathogenesis to treatment target. Seizure. 2020; 82: 65-79.

[46] Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019; 15(8): 459-472.

[47] Ho YH, Lin YT, Wu CWJ, Chao YM, Chang AYW, Chan JYH. Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus. J Biomed Sci. 2015; 22(1): 46.

[48] Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol. 2017; 81(2): 183-192.

[49] Binks S, Varley J, Lee W, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018; 141(8): 2263-2271.

[50] Catassi C, Verdu EF, Bai JC, Lionetti E. Coeliac disease. Lancet. 2022; 399(10344): 2413-2426.

[51] Verrotti A, Scaparrotta A, Olivieri C, Chiarelli F. Mechanisms in endocrinology: seizures and type 1 diabetes mellitus: current state of knowledge. Eur J Endocrinol. 2012; 167(6): 749-758.

[52] Vincent A, Crino PB. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia. 2011; 52(suppl 3): 12-17.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University and Wiley-VCH GmbH.